Advertisement

Biokinetic Models for Radiopharmaceuticals

  • Augusto GiussaniEmail author
  • Helena Uusijärvi
Chapter

Abstract

Radiopharmaceuticals administered for diagnostic or therapeutic applications in humans are selectively transported into specific organs and tissues of the body, metabolised, and finally excreted according to their biochemical and metabolic properties. Due to the presence of the radioactive label, each of the body regions containing the substance becomes an emitting source (source region), which can also irradiate the neighbouring tissues (defined as target regions). Consequently, each body organ or tissue could receive a radiation dose (absorbed dose) after administration of radiopharmaceuticals even if no activity is present in it. The absorbed dose delivered by incorporated radioactive material is called the internal dose. Direct measurements of the internal dose are not possible for evident practical reasons, so this quantity has to be calculated using a mathematical approach. Such an approach has to take into account that

Keywords

Positron Emission Tomographic Internal Dose Positron Emission Tomographic Image Biokinetic Model Identifiability Issue 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Loevinger, R., Budinger, T., and Watson, E. MIRD Primer for absorbed dose calculations. Society of Nuclear Medicine, New York (1988).Google Scholar
  2. 2.
    ICRP. Radiation dose to patients from radiopharmaceuticals. ICRP Publication 53. Ann ICRP 18(1–4) (1987).Google Scholar
  3. 3.
    ICRP. Radiation dose to patients from radiopharmaceuticals. Addendum 2 to ICRP Publication 53. ICRP Publication 80. Ann ICRP 28(3) (1998).Google Scholar
  4. 4.
    ICRP. Radiation dose to patients from radiopharmaceuticals. Addendum 3 to ICRP Publication 53. ICRP Publication 106. Ann ICRP 38(1–2) (2008).Google Scholar
  5. 5.
    Bolch, W.E., Eckerman, K.F., Sgouros, G., and Thomas, S.R. MIRD Pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry – standardization of nomenclature. J. Nucl. Med. 50:477–484 (2009).Google Scholar
  6. 6.
    ICRP. Nuclear decay data for dosimetric calculations. ICRP Publication 107. Ann ICRP 38(3) (2008).Google Scholar
  7. 7.
    Siegel, J.A., Thomas, S.R., Stubbs, J.B., Stabin, M.G., Hays, M.T., Koral, K.F., Robertson, J.S., Howell, R.W., Wessels, B.W., Fisher, D.R., et al., MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 40:37S–61S (1999).Google Scholar
  8. 8.
    Carson, E.R., Cobelli, C., and Finkelstein, L. The mathematical modelling of metabolic and endocrine systems. Wiley, New York (1983).Google Scholar
  9. 9.
    ICRP. Limits for intakes of radionuclides by workers. ICRP Publication 30 Part I. Ann ICRP 2(3–4) (1979), pp. 30–34.Google Scholar
  10. 10.
    ICRP. Human alimentary tract model for radiological protection. ICRP Publication 100. Ann ICRP 36(1–2) (2006).Google Scholar
  11. 11.
    Audoly, S., D’Angiò, L., Saccomani, M.P., and Cobelli, C. Global identifiability of linear compartment models. A computer algebra algorithm. IEEE Trans. Biomed. Eng. 45:36–47 (1998).Google Scholar
  12. 12.
    Bellù, G., Saccomani, M.P., Audoly, S., D’Angiò, L., DAISY: a new software tool to test global identifiability of biological and physiological systems. Comput. Meth. Progr. Biol. 88:52–61 (2007).Google Scholar
  13. 13.
    Loh, A., Sgouros, G., O’Donoghue, J.A., Deland, D., Puri, D., Capitelli, P., Humm, J.L., Larson, S.M., Old, L.J. and Divgi, C.R. Pharmacokinetic model of iodine-131-G250 antibody in renal cell carcinoma patients. J. Nucl. Med. 39:484–489 (1998).Google Scholar
  14. 14.
    Odom-Maryon, T.L., Williams, L.E., Chai, A., Lopatin, G., Liu, A., Wong, Y.C., Chou, J., Clarke, K.G., and Raubitschek, A.A. Pharmacokinetic modeling and absorbed dose estimation for chimeric anti-CEA antibody in humans. J. Nucl. Med. 38:1959–1966 (1997).Google Scholar
  15. 15.
    Janzen, T., Giussani, A., Canzi, C., Gerundini, P., Oeh, U., and Hoeschen, C. Investigation of biokinetics of radioiodine with a population kinetics approach. Radiat Prot. Dosim. 139:232–235 (2010).CrossRefGoogle Scholar
  16. 16.
    Cremonesi, M., Ferrari, M., Zoboli, S., Chinol, M., Stabin, M.G., Orsi, F., Maecke, H.R., Jermann, E., Robertson, C., Fiorenza, M., et al. Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC. Eur. J. Nucl. Med. 26:877–886 (1999).Google Scholar
  17. 17.
    Hays, M.T. and Segall, G.M., A mathematical model for the distribution of fluorodeoxyglucose in humans. J. Nucl. Med. 40:1358–1366 (1999).Google Scholar

Copyright information

© Springer Berlin Heidelberg 2011

Authors and Affiliations

  1. 1.Department of Medical Radiation Physics and DiagnosticsHelmholtz Zentrum MünchenNeuherbergGermany
  2. 2.Medical Radiation PhysicsLund UniversityMalmöSweden

Personalised recommendations